CBA 1535
Alternative Names: CBA-1535; Tb535HLatest Information Update: 08 Jun 2023
At a glance
- Originator Biotecnol Inc.
- Developer Chiome Bioscience
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 10 Oct 2022 Chiome Bioscience has patents pending for CBA 1535 in Europe (Chiome Bioscience pipeline, October 2022)
- 10 Oct 2022 Chiome Bioscience has patent protection for CBA 1535 in the UK, the US, China and Japan (Chiome Bioscience pipeline, October 2022)